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little doubt hat “‘in-ant~myosi~ is a rel 
safe agent for the imaging of acute infarc 
indications for its clinical usb arc less clear. 
acute myocardial infarction is easily accoInp~isbed in th 
block when electrocardiographic changes are absent or 
equivocal or when patients are evaluated several days after 
the acute event (9). From the standpoint of functional 
assessment, the technique may be of value for estimating 
infarct size, particularly inthe presence of thrombolysis and 
revascularization. The extent of “‘In-antimyosin uptake 
after infarction may also be used as a prognostic ndicator 
(10). The high affinity and selectivity of the antimyosin 
antibody for binding to the acutely necrotic myocardium 
suggest utility for detection of other conditions uch as 
myocarditis orcardiac transpla t rejection characterized by
---.- 
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owever, the precise rde of ‘:‘ln- 
vasive means of early 
ary cardiomy~~atby, 
degenerative noninfl 
still not proved, that when in~ammatory 
findings or; e~domyocardial b opsy. 
ria for the interpretation f endom 
been another source of controversy and variability ofresults 
(22,23). However, with the recent use of more uniform 
criteria for diagnosing active inflammation i  the biopsy 
specimen (24), the incidence of myocarditis in patients 
presentkg with an unexplained myopathic syndrome has 
been in the range of 10% (20). Moreover, whether biopsy 
samples of right ventricular endomyocardial tissue can be 
considered representative of the entire myocardium is an- 
other question (25). It has been shown that abnormal 
mortality, a significant minority of patients tend to stabilize 
and even improve clinically and hemodynamically. This 
proportion has not been altered by the use of specific 
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treatment. It has also not been possible to predict he 
outcome in individual cases. 
It is clear that he currently used histopathoiogic markers 
:are inadequate forthe evaluation ofpatients with myocardi- 
tis and cardiomyopathy (20). There is need for further 
markers to establish the etiology and pathogenetic mecha- 
nisms and then to develop rational therapeutic strategies. A 
number of biochemical, cytologic, ytochemical, metabolic, 
enzymatic and immunologic markers suitable for application 
to the endomyocardiai biopsy, specimen have been proposed 
and are currently under evaluation (20,27). In addition to 
mechanistic issues, there is a clear need to detect and 
quantify the various accompaniments of myocarditis, uch 
as myocyte injury, necrosis, fibrosis and inflammation, in a 
quantitative noninvasive manner. Whether “‘In-an’imyosin, 
a specific marker of myocyte necrosis, will fulfill at least 
some of these needs is worth exploring. 
The present s udy. The report by Dee et al. (28) in this 
issue of the Journal compares the findings of ” ‘In- 
antimyosin imaging with biopsy results in patients with 
suspected myocarditis. The authors observed abnormal 
“‘In-antimyosin uptake in 55% of their patients, whereas 
right ventricular endomyocardial biopsy results using the 
conventional histopathoiogic criteria indicated myocarditis 
in only 22%. Nearly all patients with abnormal biopsy results 
had abnormal “‘In-antimyosin images. It is most interesting 
that 54% of patients with an abnormal scan sliowed serial 
improvement i  left ventricular function as compared with 
only 18% of patiems with a normal scan. These changes 
occurred irrespective of the biopsy results. The decision to 
institute immunosuppressive th rapy was based only on 
histopathoiogic evidence of inflammation. Thus, patients 
with an abnormal scan but normal biopsy results did not 
receive any immunosuppressive th rapy. Nevertheless, 
their condition tended to improve, as did that of the patients 
with abnormal scan and biopsy results who also received 
immunosuppressive therapy. 
There are several issue7 concerning the study that are 
worthy of commenf: 1) The authors have repeatedly used the 
terms “sensitivity” and “specificity” in comparing the 
abnormal “‘In-antimyosin uptake and histopathologic ab- 
normalities of biopsy samples. This use of terms is confusing 
and misleading at times. “Concordance” and “discor- 
dance” might have been more appropriate rminology in
this situation because the two techniques are in part looking 
at different, although interrelated, histologic phenomena 
(inflammation a d necrosis). In addition, demonstration f 
myocarditis with the biopsy technique has a low sensitivity. 
2) “‘Inantimyosin imaging was performed inonly 82 of the 
289 eligible patients who underwent endomyocardiai biopsy 
for suspected myocarditis. A significant selection bias can- 
not be completely ruled out despite asuperficial resemblance 
between the patients who underwent “‘In-antimyosin imag- 
ing and those who did not. The clinical characteristics, 
biopsy findings and the subsequent clinical course of the 
remaining 207 patients who did not undergo “‘In-antimyosin 
imaging are not defined. 3) The authors provide no quanti- 
tative or semiquantitative approach for interpreting the 
“‘In-antimyosin images. Even a simple count-based method 
for grading the intensity of “‘In-antimyosin uptake may 
provide a reproducible and objective index of the abnormal 
tracer uptake (12). Visual qualitative image assessment may 
be variable and introduces potential subjective interpreta- 
tional issues. Also, quantified egree of uptake could be 
important functionally an ~rog~ostica~iy. The authors have 
noted heterogeneous uptake of ” 'In-antimyosin by the left 
ventricular myocardium but have not offered an explanation. 
This finding differs from that of another group (12). How did 
these images differ from the ones seen in patients with acute 
myocardial infarction? 4) The authors performed both single 
photon emission computed tomography (SPECT) and planar 
imaging, but the two techniques are not compared. Does 
SPECT imaging contribute anything additional to the planar 
imaging and is it required in ail cases? 5) Follow-up “‘In- 
antimyosin scans were obtained in only a small proportion of 
cases. It is difficult o comment about he role of serial 
“‘In-antimyosin maging in assessing the progress of the 
disease activity. However, the authors noted the persistence 
of abnormal “‘In-antimyosin localization on follow-up im- 
aging in some of their patients despite improvement i  left 
ventricular function. The explanation for this observation is 
not immediately intuitive. In patients with myocardiai in- 
farction, abnormal ’ ’ ’ In-antimyosin uptake has been ob- 
served as long as 28 to 30 weeks after the acute event even 
in the absence of any evidence of reinfarction (29,30). 
‘Though the patterns of myocardiai injury are very different 
in the two conditions, imilarities ‘nay exist regarding the 
persistence of abnormal “‘In-antimyosin uptake. Further 
studies are needed to determine the frequency and meaning 
of persistently abnormal images, as well as the most appro- 
priate time interval between consecutive “‘In-antimyosin 
studies when monitoring of ongoing disease activity is a 
major issue. 
Conclusions. Despite some limitations, the present study 
(28) demonstrates he potential of “‘In-antimyosin maging 
as a technique for the evaluation and prognostic assessment 
of patients with myocarditis orcardiomyopathy. Additional 
studies are required to explore further the role of “‘In- 
antimyosin imaging for determining disease activity an;: 
prognosis, as well as assessing the efficacy of various ther- 
apeutic modes. This technique also should have promise for 
the detection of myocardial necrosis and inflammation i
patients with acquired immunodeficiency syndrome (AIDS) 
(31) and in those with cardiotoxicity induced by antineoplas- 
tic agents like doxorubicin (32). A corn~~~e~ approach using 
gallium-67 (33) or radiolabeled leukocytes for inflammation 
imaging (34) with “‘In-antimyosin maging may provide a 
more comprehensive noninvasive picture concerning inflam- 
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